Sonoma Pharmaceuticals (NASDAQ:SNOA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) to a hold rating in a research note published on Friday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Sonoma Pharmaceuticals in a report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Sonoma Pharmaceuticals Price Performance

Shares of Sonoma Pharmaceuticals stock opened at $3.99 on Friday. Sonoma Pharmaceuticals has a fifty-two week low of $1.75 and a fifty-two week high of $6.92. The firm has a fifty day moving average price of $4.12 and a two-hundred day moving average price of $3.44. The company has a market cap of $6.56 million, a PE ratio of -1.62 and a beta of 1.46.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.14. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. The firm had revenue of $4.01 million during the quarter, compared to the consensus estimate of $4.26 million. Analysts expect that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.